ImmunityBio
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to tre...
Latest News
17 hours ago · seekingalpha.com
ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptImmunityBio, Inc. ( IBRX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Richard Adcock - President, CEO & Director Conference Call Participants Dejia Zhang Presentation Dejia Zhang My name is Dejia Zhang, and I am part of the UBS coverage team. We're very excited to host this first inaugural biotech conference here in London.
5 days ago · businesswire.com
New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to CareCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle invasive bladder cancer (NMIBC). The survey, conducted by The Harris Poll on behalf of ImmunityBio, found that 53% of respondents were diagnosed by age 50 and 63% reported barriers or challenges to receiving treatment. Respondents reported a mean age of 51.7 years at diagnosis (m.
6 days ago · businesswire.com
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference, both held in London during Life Sciences Week 2026, November 15-20. “The results from our QUILT-2.005 study bring us closer to our goal of treating bladder cancer earlier in the course of the disease,” said Richard Adcock, P.
6 days ago · zacks.com
IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.
7 days ago · fool.com
Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?ImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate. Even after Monday's drop, the stock trades at roughly 39 times its annualized sales, and the company says there is "substantial doubt" about its ability to continue without additional funding.
8 days ago · benzinga.com
ImmunityBio Reports Wider Quarterly LossImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company's third-quarter earnings missed expectations.
8 days ago · zacks.com
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue EstimatesImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
8 days ago · businesswire.com
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 MillionCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026. ImmunityBio continued to advance a broad clinical pipeline spanning bladder cancer, non-small cell lung cancer, and hematologic malignancies with expanded FDA approval and global expansion of ANKTIVA in nonmuscle invasive bladder cancer (NMIBC). AN.
8 days ago · businesswire.com
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in SituJERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA® (nogapendekin alfa inbakicept), indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Th.
8 days ago · businesswire.com
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 TrialCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical ANKTIVA® (nogapendekin alfa inbakicept-pmln/N-803) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve, high-grade non-muscle invasive bladder cance.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IBRX